memo-inOncology – SPECIAL ISSUE

Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research. Each SPECIAL ISSUE – CONGRESS REPORT features informative summaries of key topics from lung cancer to come out of a major international oncology congress.

The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.

Congress reports


Get a notification for every published memo – inOncology SPECIAL ISSUE. Register below.


    ESMO Solid Tumours 2020 English

    memo – inOncology SPECIAL ISSUE

    Congress Report virtual ESMO 2020 Solid Tumors

    A GLOBAL CONGRESS DIGEST ON SOLID TUMORS Report from the ESMO Congress, 19th – 21st September 2020, virtual congress

    ESMO 2020 Lung Cancer English

    memo – inOncology SPECIAL ISSUE

    Congress Report virtual ESMO 2020 Lung Cancer

    This report summarizes a selection of abstracts presented at ESMO 2020 Lung Cancer.

    Now available!



    All videointerviews from virtual ESMO 2020 solid tumors

    Andrés Cervantes talks about novel findings obtained in the field of gastric cancer, gastroesophageal junction adenocarcinoma and esophageal cancer as well as developments in hepatocellular carcinoma and investigational immunotherapies that might evolve into new treatment approaches.

    Eric Van Cutsem gives an overview of practice-changing results obtained for gastrointestinal cancers including colorectal cancer, gastric cancer and esophageal cancer and describes progress that has recently been made with respect to certain biomarkers.

    All videointerviews from virtual ESMO 2020 lung cancer

    Tony Mok summarizes insights into the immunotherapeutic management of patients with advanced lung cancer who receive PD-1 inhibitors and relates to aspects of biomarker-based treatment selection, patient prognosis, and new agents that might change the treatment landscape.

    Byoung Chul Cho explains about the rationale and outcomes for combined targeted treatment of lung cancer patients with an emphasis on EGFR-mutant disease and describes findings obtained for a first-in-class agent targeting the KRASG212C mutation.

    Maarten Lambrecht highlights aspects of radiobiology regarding interactions between radiotherapy and the immune system, non-invasive imaging biomarkers and trial results presented at ESMO 2020 that bear importance from a radiation oncologist’s point of view.

    Paul Baas discusses the prognosis and treatment of patients with malignant mesothelioma, relating to combined modality treatment with immune checkpoint inhibitors plus chemotherapy and talks about other immunotherapeutic approaches beyond checkpoint inhibition.